Thishighlights CGM as a potentially valuable tool in detecting andpreventing hypoglycemic events at times when POCT is lessfrequently conducted, especially in inpatients known to be atincreased risk of hypoglycemia.22 The increased detection of adverse glycemic events hasbeen found in both T1D populations requiring insulin and T2Dpopulations on basal-bolus and subcutaneous insulin in non-ICUsettings.21,22. This evidence concerns the gene INS and Hypoglycemia.